Señales en vivo de BBIO | Maximiza tus Ganancias con Getagraph.com

VENDER 40553 min ago

@ $28.73

Emitido: 8 abr 2024 @ 09:34

Retorno: -2.47%

Señal anterior: abr 4 - 11:18

Señal anterior: Comprar

Retorno: -1.44 %

Live Chart Being Loaded With Signals

Commentary (6 may 2024 @ 13:25):

Stats
Volumen de hoy	336 561
Volumen promedio	1.70M
Capitalización de mercado	5.24B
EPS	$0 ( 2024-05-02 )
Próxima fecha de ganancias	( $-0.890 ) 2024-06-21
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-8.67
ATR14	$0.0190 (0.07%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-12	Kumar Neil	Buy	313 588	Restricted Stock Units
2024-03-12	Kumar Neil	Buy	45 140	Stock Option (right to buy)
2024-03-12	Stephenson Brian C	Buy	107 278	Restricted Stock Units
2024-03-12	Stephenson Brian C	Buy	15 442	Stock Option (right to buy)
2024-03-01	Scott Randal W.	Sell	2 500	Common Stock

INSIDER POWER
-18.12
Last 100 transactions
Buy: 1 673 575 \| Sell: 2 657 073

Volumen Correlación

Largo: -0.20 (neutral)

Corto: -0.12 (neutral)

Signal:(56.962) Neutral

BridgeBio Pharma Inc Correlación

10 Correlaciones Más Positivas
ALTR	0.941
RRGB	0.928
ANSS	0.928
SVC	0.927
RCEL	0.925
LPSN	0.925
AUUD	0.925
PLYA	0.923
PDFS	0.923
NARI	0.921

10 Correlaciones Más Negativas
NAKD	-0.928
GXII	-0.921
GSMG	-0.921
JUPW	-0.919
RAM	-0.915
PIXY	-0.913
AEAC	-0.913
CEG	-0.912
KINS	-0.911
SNGX	-0.911

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

BridgeBio Pharma Inc Correlación - Moneda/Commodity

-0.36
( neutral )

-0.23
( neutral )

0.00
( neutral )

-0.40
( neutral )

0.35
( neutral )

0.14
( neutral )

BridgeBio Pharma Inc Finanzas

Annual	2023
Ingresos:	$9.30M
Beneficio Bruto:	$6.86M (73.71 %)
EPS:	$-3.95

FY	2023
Ingresos:	$9.30M
Beneficio Bruto:	$6.86M (73.71 %)
EPS:	$-3.95

FY	2022
Ingresos:	$77.65M
Beneficio Bruto:	$74.21M (95.58 %)
EPS:	$-3.35

FY	2021
Ingresos:	$69.72M
Beneficio Bruto:	$66.60M (95.53 %)
EPS:	$-4.77

Financial Reports:

No articles found.

BridgeBio Pharma Inc

BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor, which is Phase 2 clinical trial to treat achondroplasia in pediatric patients; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 2 proof-of-concept clinical trial for Autosomal Dominant Hypocalcemia Type 1, or ADH1; and BBP-711 for the treatment of hyperoxaluria, as well as patients suffering from recurrent kidney stones. In addition, it engages in developing products for Mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and The Regents of the University of California; Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.